中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 6
Jun.  2018
Turn off MathJax
Article Contents

Clinical features of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China

DOI: 10.3969/j.issn.1001-5256.2018.06.029
  • Received Date: 2017-11-21
  • Published Date: 2018-06-20
  • Objective To investigate the clinical manifestations, treatment, and prognosis of sinusoidal obstruction syndrome induced by pyrrolidine alkaloids in China. Methods Related databases were searched, and 107 articles on sinusoidal obstruction syndrome published from January 1980 to April 2017 in China were included, with 407 patients in total. Related data of this disease were analyzed, including sex, age, regional distribution, clinical manifestations, imaging and pathological findings, and prognosis. Results The male/female ratio of 407 patients was 1: 1. 22, and the age of onset ranged from 13 months to 81 years. Major clinical manifestations included abdominal distension, abdominal pain, ascites, and hepatomegaly. The most typical abdominal CT findings were hepatomegaly and a map-like or patchy change after enhancement. Pathological examination showed sinusoidal expansion and congestion and varying degrees of stenosis of small hepatic veins. Of all 407 patients, 302 had response and 90 died, resulting in a mortality rate of 22. 1%. Conclusion In China, the male population has a higher incidence rate of sinusoidal obstruction syndrome than the female population, and sinusoidal obstruction syndrome can occur at any age. Major clinical manifestations include abdominal distension, abdominal pain, ascites, and hepatomegaly, which can be used to make a definite diagnosis in combination with typical liver CT manifestations. Pathological findings by liver biopsy are the gold standard for diagnosis. Symptomatic treatment is the major treatment modality, and some patients may have poor prognosis.

     

  • loading
  • [1]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1633.
    [2]DIGNAN FL, WYNN RF, HADZICH N, et al.BCSH/BSBMT guideline:Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J].Br J Haematol, 2013, 163 (4) :444-457.
    [3]LI HN, ZHANG M.Research advances in sinusoidal obstruction syndrome[J].J Clin Hepatol, 2016, 32 (7) :1429-1432. (in Chinese) 厉海妮, 张民.肝窦阻塞综合征的研究进展[J].临床肝胆杂志, 2016, 32 (7) :1429-1432.
    [4]DALLE JH, GIRALT SA.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:Risk factors and stratification, prophylaxis, and treatment[J].Biol Blood Marrow Transplant, 2016, 22 (3) :400-409.
    [5]CHEN Z, HUO JR.Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal prearations[J].Neth J Med, 2010, 68 (6) :252-260.
    [6]WU YH, WU QH.Clinical characteristics of hepatic veno-occlusive disease by senecio chrysanthemoides:Analysis of 9 cases[J].China Med Herald, 2016, 13 (35) :161-163. (in Chinese) 吴玉华, 武谦虎.土三七致肝小静脉闭塞症9例临床分析[J].中国医药导报, 2016, 13 (35) :161-163.
    [7]WANG JY, GAO H.Tusanqi and hepatic sinusoidal obstruction syndrome[J].J Dig Dis, 2014, 15 (3) :105-107.
    [8]SONG Y, FAN YH.Clinical features of hepatic veno-occlusive disease induced by gynura root:analysis of 102 cases[J].J Clin Hepatol, 2011, 27 (5) :496-499. (in Chinese) 宋宇, 樊艳华.土三七所致肝小静脉闭塞病102例临床分析[J].临床肝胆病杂志, 2011, 27 (5) :496-499.
    [9] ZHANG YL.Sinusoidal obstruction syndrome in children[J].Chin Pediatr Emerg Med, 2012, 19 (4) :442-443. (in Chinese) 张艳玲.儿童肝窦阻塞综合征[J].中国小儿急救医学, 2012, 19 (4) :442-443.
    [10]CHEN Y, XU XG, CHEN F.Hepatic veno-occlusive disease in children:A case report and literature review[J].J Taishan Med Coll, 2017, 38 (6) :689-690. (in Chinese)
    [11]GAO H, RUAN JQ, CHEN J, et al.Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome[J].Drug Des Devel Ther, 2015, 9:4861-4868.
    [12]LEE JH.Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation[J].Blood Res, 2015, 50 (3) :123-125.
    [13]GUO W, SHI HP, MA XX.The diagnosis of sinusoidal obstruction syndrome based on CT findings[J/CD].Chin J Clinicians:Electronic Edition, 2012, 6 (13) :3722-3726. (in Chinese) 郭薇, 时惠平, 马晓璇.肝窦阻塞综合征CT诊断[J/CD].中华临床医师杂志:电子版, 2012, 6 (13) :3722-3726.
    [14]WU YF, LIU JH, ZHU BQ.Clinicopathological features of hepatic veno-occlusive disease:an analysis of 10 cases[J].Guide China Med, 2016, 14 (29) :110. (in Chinese) 吴云飞, 刘健红, 朱冰清, 等.10例肝窦阻塞综合征 (HVOD) 的临床病理分析[J].中国医药指南, 2016, 14 (29) :110.
    [15]SONG JS, SEO JJ, MOON HN, et al.Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children[J].J Korean Med Sci, 2006, 21 (5) :897-903.
    [16]IBRAHIM R, PERES E, DANSEY R, et al.Anti-thrombin in the management of hematopoietic stem-cell transplantation associated toxicity[J].Ann Pharmacother, 2004, 38 (6) :1053-1059.
    [17]RICHARDSON PG, HO VT, GIRALT S, et al.Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease[J].Ther Adv Hematol, 2012, 3 (4) :253-265.
    [18]RICHARDSON P, MURAKAMI C, JIN Z, et al.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:Response without significant toxicity in a high-risk population and factors predictive of outcome[J].Blood, 2002, 100 (13) :4337-4434.
    [19]RICHARDSON PG, SMITH AR, TRIPLETT BM, et al.Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome:Interim results from a treatment IND study[J].Biol Blood Marrow Transplant, 2017, 23 (6) :997-1004.
    [20]BAGAL B, CHANDRASEKHARAN A, CHOUGLE A, et al.Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation[J].Hematol Oncol Stem Cell Ther, 2018, 11 (1) :47-51.
    [21]HELMY A.Review article:updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome[J].Aliment Pharmacol Ther, 2006, 23 (1) :11-25.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (348) PDF downloads(204) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return